XML 73 R52.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Business Segments (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2024
Segment Reporting [Abstract] |
Information about our Operating and Reportable Segments | The tables below summarize information about our operating and reportable segments.
| Year Ended March 31, 2024
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 958,260 |  |  | $ | 167,097 |  |  |  |  | $ | 1,125,357 |
Cost of sales | 429,361 |  |  | 71,548 |  |  |  |  | 500,909 |
Gross profit | 528,899 |  |  | 95,549 |  |  |  |  | 624,448 |
Advertising and marketing | 131,494 |  |  | 21,821 |  |  |  |  | 153,315 |
Contribution margin | $ | 397,405 |  |  | $ | 73,728 |  |  |  |  | 471,133 |
Other operating expenses |  |  |  |  |  |  | 128,704 |
Operating income |  |  |  |  |  |  | $ | 342,429 |
*Intersegment revenues of $3.7 million were eliminated from the North American OTC Healthcare segment.
| Year Ended March 31, 2023
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 973,774 |  |  | $ | 153,951 |  |  |  |  | $ | 1,127,725 |
Cost of sales | 441,844 |  |  | 60,587 |  |  |  |  | 502,431 |
Gross profit | 531,930 |  |  | 93,364 |  |  |  |  | 625,294 |
Advertising and marketing | 123,926 |  |  | 21,135 |  |  |  |  | 145,061 |
Contribution margin | $ | 408,004 |  |  | $ | 72,229 |  |  |  |  | 480,233 |
Other operating expenses** |  |  |  |  |  |  | 502,648 |
Operating loss |  |  |  |  |  |  | $ | (22,415) |
* Intersegment revenues of $4.3 million were eliminated from the North American OTC Healthcare segment. **Other operating expenses for the year ended March 31, 2023 includes a tradename impairment charge of $321.4 million and a goodwill impairment charge of $48.8 million.
| Year Ended March 31, 2022
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 967,881 |  |  | $ | 118,931 |  |  |  |  | $ | 1,086,812 |
Cost of sales | 419,162 |  |  | 47,004 |  |  |  |  | 466,166 |
Gross profit | 548,719 |  |  | 71,927 |  |  |  |  | 620,646 |
Advertising and marketing | 138,714 |  |  | 18,629 |  |  |  |  | 157,343 |
Contribution margin | $ | 410,005 |  |  | $ | 53,298 |  |  |  |  | 463,303 |
Other operating expenses |  |  |  |  |  |  | 133,384 |
Operating income |  |  |  |  |  |  | $ | 329,919 |
*Intersegment revenues of $3.0 million were eliminated from the North American OTC Healthcare segment.
Information about our Revenues from Similar Product Groups | The tables below summarize information about our segment revenues from similar product groups.
| Year Ended March 31, 2024
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 111,996 |  |  | $ | 5,455 |  |  |  |  | $ | 117,451 |
Cough & Cold | 93,575 |  |  | 25,445 |  |  |  |  | 119,020 |
Women's Health | 217,103 |  |  | 23,318 |  |  |  |  | 240,421 |
Gastrointestinal | 160,889 |  |  | 70,721 |  |  |  |  | 231,610 |
Eye & Ear Care | 156,553 |  |  | 22,870 |  |  |  |  | 179,423 |
Dermatologicals | 123,288 |  |  | 5,814 |  |  |  |  | 129,102 |
Oral Care | 83,212 |  |  | 13,093 |  |  |  |  | 96,305 |
Other OTC | 11,644 |  |  | 381 |  |  |  |  | 12,025 |
Total segment revenues | $ | 958,260 |  |  | $ | 167,097 |  |  |  |  | $ | 1,125,357 |
| Year Ended March 31, 2023
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 116,582 |  |  | $ | 2,680 |  |  |  |  | $ | 119,262 |
Cough & Cold | 100,218 |  |  | 26,770 |  |  |  |  | 126,988 |
Women's Health | 231,754 |  |  | 19,597 |  |  |  |  | 251,351 |
Gastrointestinal | 156,957 |  |  | 69,626 |  |  |  |  | 226,583 |
Eye & Ear Care | 151,879 |  |  | 19,197 |  |  |  |  | 171,076 |
Dermatologicals | 119,822 |  |  | 3,919 |  |  |  |  | 123,741 |
Oral Care | 85,542 |  |  | 12,085 |  |  |  |  | 97,627 |
Other OTC | 11,020 |  |  | 77 |  |  |  |  | 11,097 |
Total segment revenues | $ | 973,774 |  |  | $ | 153,951 |  |  |  |  | $ | 1,127,725 |
| Year Ended March 31, 2022
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 117,868 |  |  | $ | 1,455 |  |  |  |  | $ | 119,323 |
Cough & Cold | 86,855 |  |  | 20,225 |  |  |  |  | 107,080 |
Women's Health | 249,136 |  |  | 15,373 |  |  |  |  | 264,509 |
Gastrointestinal | 152,191 |  |  | 52,368 |  |  |  |  | 204,559 |
Eye & Ear Care | 149,454 |  |  | 13,995 |  |  |  |  | 163,449 |
Dermatologicals | 117,173 |  |  | 3,213 |  |  |  |  | 120,386 |
Oral Care | 85,239 |  |  | 12,282 |  |  |  |  | 97,521 |
Other OTC | 9,965 |  |  | 20 |  |  |  |  | 9,985 |
Total segment revenues | $ | 967,881 |  |  | $ | 118,931 |  |  |  |  | $ | 1,086,812 |
Segment Revenue by Geographic Area | Our total segment revenues by geographic area are as follows:
| Year Ended March 31,
| 2024 |  | 2023 |  | 2022
United States | $ | 886,470 |  |  | $ | 953,222 |  |  | $ | 910,106 |
Rest of world | 238,887 |  |  | 174,503 |  |  | 176,706 |
Total | $ | 1,125,357 |  |  | $ | 1,127,725 |  |  | $ | 1,086,812 |
Allocation of Long-Term Assets to Segments | Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:
March 31, 2024 (In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Goodwill | $ | 498,936 |  |  | $ | 28,797 |  |  |  |  | $ | 527,733 |
Intangible assets |  |  |  |  |  |  |
Indefinite-lived | 2,092,853 |  |  | 74,309 |  |  |  |  | 2,167,162 |
Finite-lived | 135,932 |  |  | 17,489 |  |  |  |  | 153,421 |
Intangible assets, net | 2,228,785 |  |  | 91,798 |  |  |  |  | 2,320,583 |
Total | $ | 2,727,721 |  |  | $ | 120,595 |  |  |  |  | $ | 2,848,316 |
March 31, 2023 (In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Goodwill | $ | 498,936 |  |  | $ | 28,617 |  |  |  |  | $ | 527,553 |
Intangible assets |  |  |  |  |  |  |
Indefinite-lived | 2,092,852 |  |  | 76,050 |  |  |  |  | 2,168,902 |
Finite-lived | 154,552 |  |  | 18,439 |  |  |  |  | 172,991 |
Intangible assets, net | 2,247,404 |  |  | 94,489 |  |  |  |  | 2,341,893 |
Total | $ | 2,746,340 |  |  | $ | 123,106 |  |  |  |  | $ | 2,869,446 |
Goodwill and Intangible Assets by Geographic Areas | Our goodwill and intangible assets by geographic area are as follows:
| Year Ended March 31,
| 2024 |  | 2023
United States | $ | 2,727,721 |  |  | $ | 2,746,340 |
Rest of world | 120,595 |  |  | 123,106 |
Total | $ | 2,848,316 |  |  | $ | 2,869,446 |

X
- Definition [Table Text Block] for Goodwill and Intangible Assets by Geographic Areas [Table] + References No definition available. + Details
Name: | pbh_GoodwillandIntangibleAssetsbyGeographicAreasTableTextBlock
Namespace Prefix: | pbh_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph a -SubTopic 10 -Topic 280 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration